All stock lists
Enliven Therapeutics, Inc. (NASDAQ:ELVN)
US · Delayed Price · Currency is USD
Healthcare · Biotechnology
41.52-0.41 (-0.98%)
Insider Score
––Not scored
ELVN Insider Score
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
ELVN Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 |
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Growth (YoY) | — | — | — | — | — | — |
| Cost of Revenue | 0.00 | 14.00 K | 46.00 K | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | -14.00 K | -46.00 K | 0.00 | 0.00 | 0.00 |
| SG&A Expense | 8.21 M | 7.14 M | 13.04 M | 6.87 M | 7.09 M | 6.80 M |
| R&D Expense | 29.00 M | 20.69 M | 21.25 M | 18.23 M | 21.49 M | 24.89 M |
| Operating Expenses | 37.21 M | 27.82 M | 34.24 M | 25.10 M | 28.58 M | 31.69 M |
| Operating Income | -37.21 M | -27.82 M | -34.28 M | -25.10 M | -28.58 M | -31.69 M |
| Pretax Income | -32.48 M | -23.63 M | -29.67 M | -20.15 M | -25.34 M | -28.54 M |
| Tax Provision | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -32.48 M | -23.63 M | -29.67 M | -20.15 M | -25.34 M | -28.54 M |
| EPS (Basic) | -0.49 | -0.38 | -0.45 | -0.32 | -0.49 | -0.57 |
| EPS (Diluted) | -0.49 | -0.38 | -0.45 | -0.32 | -0.49 | -0.57 |
| Shares Outstanding | 66.17 M | 62.80 M | 56.66 M | 62.09 M | 52.11 M | 50.05 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.